Methods to Evaluate Bioavailability

Measurement of Bioavailability Bioavailability is a fundamental concept in pharmacology and nutrition science that measures how much of an administered dose reaches systemic circulation. Understanding bioavailability requires learning how to quantify it using plasma concentration data and how to compare different drug formulations or administration routes. This module covers the key methods for measuring bioavailability and the standards used to evaluate whether different formulations of the same drug are therapeutically equivalent. What Is Bioavailability and Why It Matters Bioavailability describes the fraction of an administered dose that reaches systemic circulation in unchanged form. When you take a drug intravenously, 100% of the dose enters the bloodstream directly. However, with other routes—oral, transdermal, nasal, or others—some of the drug may be absorbed incompletely, or broken down before reaching the bloodstream. Bioavailability quantifies these differences, which has major implications for dosing and therapeutic effectiveness. Determining Bioavailability: The Area Under the Curve (AUC) The primary tool for measuring bioavailability is the Area Under the Curve (AUC), which represents the total exposure of the body to a drug over time. To obtain an AUC, researchers collect blood samples at multiple time points after drug administration and measure the drug's plasma concentration at each timepoint. When plotted on a graph with plasma concentration on the y-axis and time on the x-axis, the area between this curve and the x-axis is the AUC. The AUC mathematically represents the total amount of unchanged drug that reaches systemic circulation over time. A larger AUC indicates greater systemic exposure; a smaller AUC indicates less exposure. Because AUC integrates concentration across all timepoints, it captures the complete picture of drug exposure better than any single measurement could. The figure above illustrates this concept. The red shaded area represents the AUC after intravenous (IV) administration, while the blue shaded area represents the AUC after oral (po, meaning "per os" or by mouth) administration. Notice that the IV dose produces a higher initial concentration and a different curve shape compared to the oral dose, even though you started with the same amount of drug. Absolute Bioavailability: Comparing Routes to Intravenous Absolute bioavailability answers this question: If we give the same drug intravenously versus by another route (oral, nasal, transdermal, rectal, buccal, sublingual, or subcutaneous), how much less drug reaches systemic circulation with the non-intravenous route? Absolute bioavailability is always expressed as a fraction or percentage, where intravenous administration serves as the reference standard. By definition, IV administration has absolute bioavailability equal to 1.0 (or 100%), since all of the dose enters the bloodstream directly. The Absolute Bioavailability Formula The formula for absolute bioavailability ($F$) is: $$F = \frac{\text{AUC}{\text{non-IV}} / \text{Dose}{\text{non-IV}}}{\text{AUC}{\text{IV}} / \text{Dose}{\text{IV}}}$$ This formula compares the plasma exposure per unit dose for a non-intravenous route against the plasma exposure per unit dose for intravenous administration. Notice that we divide AUC by dose—this is crucial because it normalizes for differences in the amount of drug given, allowing a fair comparison even if the IV and non-IV doses differ. Why divide by dose? Imagine comparing oral and IV administration of a drug. If you gave 100 mg orally but only 50 mg intravenously, the oral route would naturally have a larger AUC simply because you administered more drug. By calculating AUC per unit dose, you isolate the true difference in absorption and availability between the routes. Study Design Requirements Determining absolute bioavailability requires a crossover study design (or parallel group design) where the same subjects receive the drug via both intravenous and non-intravenous routes at different times. Researchers must collect plasma concentration-time data after each administration, measure the AUC for each route, and apply the formula above. This dual-administration requirement creates a practical limitation: for any non-intravenous route to be tested, an intravenous formulation must exist. Developing an IV formulation entails additional toxicity testing, manufacturing challenges, and costs—which explains why not all drugs have proven absolute bioavailability values. Typical Values and Regulatory Considerations Most non-intravenous routes produce absolute bioavailability less than 100%. For example, oral drugs commonly show 50-90% bioavailability because some drug is destroyed by stomach acid or liver enzymes before reaching systemic circulation (a process called first-pass metabolism). Some routes like sublingual or transdermal may achieve higher bioavailability by bypassing the liver initially, but they rarely reach 100%. When do regulators care about absolute bioavailability? Regulatory agencies (like the FDA) typically request absolute bioavailability data when: The extravascular route shows low or highly variable bioavailability There is a clear pharmacodynamic-pharmacokinetic relationship (meaning systemic exposure directly predicts the drug's effect) In these situations, knowing absolute bioavailability helps ensure patients receive adequate drug exposure for therapeutic benefit. Relative Bioavailability and Bioequivalence While absolute bioavailability compares an extravascular route to IV administration, relative bioavailability compares two different formulations or products of the same drug administered by the same route. Definition and Purpose Relative bioavailability answers: "If I switch from Product A to Product B (both oral tablets, for example), will my body absorb the same amount of drug?" This is especially important when a brand-name drug goes off patent and generic versions enter the market. Two tablets containing the same active ingredient may have different inactive ingredients (excipients), coating materials, or manufacturing methods that affect how much drug your body actually absorbs. Relative bioavailability is calculated similarly to absolute bioavailability, but instead of comparing IV to non-IV routes, you compare one formulation to a reference formulation: $$\text{Relative Bioavailability} = \frac{\text{AUC}{\text{test formulation}} / \text{Dose}{\text{test}}}{\text{AUC}{\text{reference formulation}} / \text{Dose}{\text{reference}}}$$ Bioequivalence: The FDA Standard Bioequivalence is a regulatory term meaning that two formulations deliver the drug to systemic circulation at nearly the same rate and extent. For the FDA, generic drugs must demonstrate bioequivalence to the brand-name reference product. The FDA's bioequivalence criterion is that the 90% confidence interval for the ratio of mean AUC and mean Cmax (maximum concentration) must fall within 80–125% of the reference product. In simpler terms: If a reference product achieves an AUC of 1000 ng·h/mL, the generic version's AUC must fall between 800 and 1250 ng·h/mL on average (with 90% statistical confidence). The same 80–125% criterion applies to Cmax, the highest plasma concentration achieved. This range ensures that generic drugs are therapeutically equivalent—patients will experience the same clinical effects whether they take the brand name or generic version. Key Pharmacokinetic Parameters in Bioequivalence When evaluating whether two formulations are bioequivalent, three plasma concentration parameters are assessed: Area Under the Curve (AUC): Reflects the total systemic exposure to the drug over time. A larger AUC means more total drug reaches the bloodstream. This is the most important parameter because it directly indicates how much active drug is available to produce therapeutic effects. Maximum Concentration (Cmax): The highest plasma concentration reached. Cmax matters because it relates to the intensity of the drug's effect—some drugs work better if they reach higher peak concentrations, while others may cause toxicity at high peaks. Time to Maximum Concentration (Tmax): The clock time at which Cmax is reached. While the FDA does not enforce a strict confidence interval for Tmax (unlike AUC and Cmax), this parameter still matters clinically. For example, if one formulation reaches peak concentration in 30 minutes and another in 3 hours, patients might experience differences in symptom relief timing even if the total exposure (AUC) is identical. <extrainfo> Bioavailability in Nutrition Science In nutrition research and supplement science, relative bioavailability is the most common measure. Researchers frequently compare different formulations of the same dietary ingredient—for instance, comparing the bioavailability of iron from a ferrous sulfate tablet versus iron from a food-based supplement. This helps consumers and health professionals understand whether different supplement brands or forms deliver equivalent amounts of the nutrient to the body. Formulation Factors and Future Challenges Formulation factors—such as tablet coating, particle size, inclusion of absorption enhancers, and interaction with food—heavily influence bioavailability. These factors have been extensively studied for pharmaceutical drugs, leading to well-established design principles for drug formulations. For nutritional supplements, however, such systematic research is less advanced. As the supplement industry grows and regulatory scrutiny increases, more attention is being paid to understanding how formulation choices affect bioavailability of vitamins, minerals, and botanical ingredients. </extrainfo>